Akoya Biosciences, Inc.(AKYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKYA Akoya Biosciences, Inc.

Trading 03-28 13:31:10 EDT

1.39

-0.10

-7.05%

High1.49	Low1.39	Vol39.44K
Open1.49	D1 Closing1.49	Amplitude7.05%
Mkt Cap69.00M	Tradable Cap21.32M	Total Shares49.82M
T/O55.62K	T/O Rate0.26%	Tradable Shares15.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"AKYA","market":"US","secType":"STK","nameCN":"Akoya Biosciences, Inc.","latestPrice":1.385,"timestamp":1743183035140,"preClose":1.49,"halted":0,"volume":39442,"delay":0,"floatShares":15393782,"shares":49816357,"eps":-1.120328,"marketStatus":"Trading","change":-0.105,"latestTime":"03-28 13:31:10 EDT","open":1.49,"high":1.49,"low":1.385,"amount":55620.209122399996,"amplitude":0.07047,"askPrice":1.39,"askSize":600,"bidPrice":1.38,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.120328,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":1.49,"postHourTrading":{"tag":"盘后","latestPrice":1.49,"preClose":1.49,"latestTime":"18:32 EDT","volume":4151,"amount":6185.859,"timestamp":1743114727344},"volumeRatio":0.410086,"impliedVol":1.2541,"impliedVolPercentile":0.4},"requestUrl":"/m/hq/s/AKYA","defaultTab":"news","newsList":[{"id":"2522881516","title":"Akoya Biosciences Shares Fall After Downgrade From Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2522881516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522881516?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:53","pubTimestamp":1742928822,"startTime":"0","endTime":"0","summary":"Akoya Biosciences  shares were down 8% in recent trading Tuesday after Stephens downgraded the stock to equalweight from overweight with a $1.80 price target.The company's trading volume stood at about 136,000 shares against a daily average of roughly 685,000.Price: 1.54, Change: -0.14, Percent Change: -8.08","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKYA"],"gpt_icon":0},{"id":"2522003016","title":"Akoya Biosciences Cut to Equal-Weight From Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003016","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003016?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 22:42","pubTimestamp":1742913720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 10:42 ET (14:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA"],"gpt_icon":0},{"id":"2522604056","title":"Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2522604056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522604056?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 18:48","pubTimestamp":1742899694,"startTime":"0","endTime":"0","summary":"Akoya Biosciences (AKYA) has an average rating of hold and mean price target of $3.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKYA"],"gpt_icon":0},{"id":"2522319044","title":"Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2522319044","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522319044?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 18:17","pubTimestamp":1742897853,"startTime":"0","endTime":"0","summary":"Akoya Biosciences (AKYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mason Carrico from...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-akoya-biosciences-amid-acquisition-uncertainties-and-mixed-financial-performance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-akoya-biosciences-amid-acquisition-uncertainties-and-mixed-financial-performance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","AKYA","BK4121"],"gpt_icon":0},{"id":"2521401387","title":"BRIEF-Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2521401387","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521401387?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:18","pubTimestamp":1742818708,"startTime":"0","endTime":"0","summary":"BRIEF-Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya BiosciencesMarch 24 (Reuters) - Akoya Biosciences Inc AKYA.O:TIKVAH MANAGEMENT- ANNOUNCES INTENTION T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","AKYA","BK4539"],"gpt_icon":0},{"id":"2521612747","title":"Tikvah Management- Announces Intention to Vote Against Quanterix's Proposed Merger With Akoya Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2521612747","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521612747?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:02","pubTimestamp":1742817742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4121","AKYA"],"gpt_icon":0},{"id":"2521745064","title":"Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745064","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745064?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:45","pubTimestamp":1742813120,"startTime":"0","endTime":"0","summary":"Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Hold rating on Akoya Biosciences (AKYA – Research Report), retaining the price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/hold-rating-on-akoya-biosciences-amid-acquisition-uncertainties-and-financial-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/hold-rating-on-akoya-biosciences-amid-acquisition-uncertainties-and-financial-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKYA"],"gpt_icon":0},{"id":"2521710692","title":"North American Morning Briefing: Stock Futures Rise on Tariff Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2521710692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521710692?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:25","pubTimestamp":1742811900,"startTime":"0","endTime":"0","summary":"Stock futures jumped Monday, boosted by relief that the next barrage of tariffs could be narrower than previously feared.The White House is narrowing its approach to tariffs  set to take effect on April 2.It will likely leave out tariffs on specific industries while applying reciprocal charges on some major trading partners.This week's full slate of data releases  could easily reignite volatility in a stock market already feeling uneasy about the economy, according to market analysts.GameStop, Dollar Tree, and Lululemon  are all due to report earnings during the week.Azek stock  rose 18% after it agreed to be acquired by Australian-listed James Hardie Industries.MicroStrategy rose 4.7%. The major Bitcoin investor lowered the price of its coming preferred stock offering.In a filing Friday it said it would sell perpetual preferred stock at $85 a share, 15% below the $100 price it originally expected. The company, however, increased the size of its offering and now will sell 8.5 million s","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AERG","AFG","ATIP","BK4587","ET","BIOA","CFNB","AKYA","BK4196","BZFD","BK4077","BK4164","BK4111","BK4581","BK4107","BK4590","BK4121","BK4561","BK4187","BK4007","OP.USD.HKCC","BK4588","BK4144","BK4585","BK4117","BK4539"],"gpt_icon":0},{"id":"2520608370","title":"Akoya Biosciences Price Target Maintained With a $3.50/Share by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520608370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520608370?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 21:50","pubTimestamp":1742305800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 09:50 ET (13:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA"],"gpt_icon":0},{"id":"2520567260","title":"Q4 2024 Quanterix Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520567260","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520567260?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 21:18","pubTimestamp":1742303907,"startTime":"0","endTime":"0","summary":"Joshua Young; Head of Investor Relations; Quanterix Corp. Masoud Toloue; President, Chief Executive Officer, Director; Quanterix Corp. Matthew Sykes; Analyst; The Goldman Sachs Group, Inc.Thank you for standing by. My name is Kathleen and I will be your conference operator today. At this time, I would like to welcome everyone to the Quanterix Corporation fourth-quarter 2024 earnings call.  Thank you. Now, I would like to turn the call over to Joshua Young, Head of Investor Relations. Please go ahead.Thank you, Joshua. I'm pleased to report that Quanterix delivered our seventh consecutive quarter of double-digit revenue growth, driven by robust demand","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-quanterix-corp-earnings-131827291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKYA","QTRX"],"gpt_icon":0},{"id":"2520389686","title":"Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520389686","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520389686?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 05:10","pubTimestamp":1742245803,"startTime":"0","endTime":"0","summary":"Akoya Biosciences  came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this tissue analysis provider would post a loss of $0.19 per share when it actually produced a loss of $0.18, delivering a surprise of 5.26%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 30% of the 250 plus Zacks industries. Ou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akoya-biosciences-akya-reports-q4-211003252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKYA"],"gpt_icon":0},{"id":"2520928500","title":"Akoya Biosciences Q4 2024 GAAP EPS $(0.17) Misses $(0.16) Estimate, Sales $21.344M Beat $21.338M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520928500","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520928500?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:03","pubTimestamp":1742241818,"startTime":"0","endTime":"0","summary":"Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 22.73 percent increase over losses of $(0.22) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44363962/akoya-biosciences-q4-2024-gaap-eps-0-17-misses-0-16-estimate-sales-21-344m-beat-21-338m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Akoya Biosciences Q4 2024 GAAP EPS $(0.17) Misses $(0.16) Estimate, Sales $21.344M Beat $21.338M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA"],"gpt_icon":0},{"id":"2520500670","title":"Akoya Biosciences Inc  Q4 Shr View $-0.16, REV View $21.3 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2520500670","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520500670?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:01","pubTimestamp":1742241668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00R3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKYA","BK4121","QTRX","BK4539"],"gpt_icon":0},{"id":"2520500620","title":"Akoya Biosciences Inc Qtrly Revenue Was $21.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520500620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520500620?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:01","pubTimestamp":1742241668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00R3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","QTRX","AKYA","BK4121"],"gpt_icon":0},{"id":"2520500634","title":"Press Release: Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520500634","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520500634?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:00","pubTimestamp":1742241600,"startTime":"0","endTime":"0","summary":"MARLBOROUGH, Mass., March 17, 2025  -- Akoya Biosciences, Inc.  , The Spatial Biology Company , today announced its financial results for the fourth quarter and full year ending December 31, 2024.\"Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions,\" said Brian McKelligon, CEO of Akoya. \"In 2024, Akoya achieved multiple milestones, including expanding our market-leading installed base to 1,330 instruments, launching our Manufacturing Center of Excellence to drive improvements in gross margins and the expansion of our content menu into new markets like neurobiology, and continued advancement of our clinical partnerships led by Acrivon and NeraCare.\". -- Revenue was $21.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4022","R","BK4232","BK4121","AKYA"],"gpt_icon":0},{"id":"2520500576","title":"Press Release: Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520500576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520500576?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:00","pubTimestamp":1742241600,"startTime":"0","endTime":"0","summary":"Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call. Believes Proposed Transaction with Akoya Significantly Undervalues Quanterix. Encourages Shareholders to Vote Against Transaction to Protect Long-Term Value of their Investment. Kent Lake PR LLC  is a holder of 7.47% of the outstanding common stock of Quanterix Corporation  . Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction  with Akoya Biosciences  , and has also nominated three highly qualified, independent candidates for election to the Company's Board of Directors .Kent Lake urges Quanterix management to address the following questions related to the Transaction on its earnings call today:. enterprise value to Akoya shareholders and less than 18% to Quanterix. -- Akoya Going Concern: When evaluating Akoya's liquidity and going concern. which awards Akoya shareholders a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","AKYA"],"gpt_icon":0},{"id":"2518720743","title":"Sector Update: Health Care Stocks Slide in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2518720743","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518720743?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 02:01","pubTimestamp":1741716092,"startTime":"0","endTime":"0","summary":"Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling about 1.5%.The iShares Biotechnology ETF (IBB) dropped 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKYA","SGXZ57979304.SGD","BK4533","IE00B19Z3581.USD","LU1894683264.USD","BK4588","LU0234572021.USD","BK4568","PFE.AU","IE0002270589.USD","LU0321505868.SGD","LU0225771236.USD","SG9999003800.SGD","BK4581","SG9999001176.USD","LU0058720904.USD","LU1883839398.USD","BK4007","BK4534","LU0868494617.USD","LU1066053197.SGD","SG9999011175.SGD","LU0289739699.SGD","LU0985481810.HKD","BK4539","LU1057294990.SGD","SG9999002224.SGD","LU0456855351.SGD","BK4550","BK4535","GH","IBB","IE00BLSP4239.USD","BK7095","IE00BLSP4452.SGD","LU0306806265.USD","LU1894683348.USD","SG9999013999.USD","BK4196","ARVN","LU0321505439.SGD","IE000M9KFDE8.USD","LU1023059063.AUD","QTRX","XLV","LU0225284248.USD","BK4585","BK4592","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2518728896","title":"Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2518728896","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518728896?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:39","pubTimestamp":1741703964,"startTime":"0","endTime":"0","summary":"Quanterix  shareholder Kent Lake said Tuesday that it opposes the company's proposed deal with Akoya Biosciences .Kent Lake, which owns 7.25% of Quanterix's stock, argued the deal is bad for Quanterix shareholders as it values Akoya almost five times higher than Quanterix, despite Quanterix's \"superior\" growth and market opportunity.Kent Lake said in its claims that Quanterix ended up bidding against itself for Akoya, as other potential buyers backed out. It also raised concerns about the Quanterix board, suggesting that some directors have conflicts of interest and have not acted in the best interests of shareholders.Kent Lake urged Quanterix stockholders to vote against the proposed merger and also said it recently nominated three independent board candidates to represent shareholders' interests better.Quanterix and Akoya Biosciences did not immediately reply to MT Newswires' request for comments.QTRX shares were up 3.5% and AKYA shares were 5.2% higher in recent trading.Price: 7.53,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4121","QTRX","AKYA"],"gpt_icon":0},{"id":"2518743089","title":"Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2518743089","media":"Business Wire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518743089?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"Highlights that Quanterix’s Board is Essentially Rescuing Akoya at the Direct Expense of Quanterix Shareholders. Transaction Would Introduce Unnecessary Risk and Divert Cash and Management Focus Away from Quanterix’s Alzheimer’s Diagnostics Program, a Core Growth Opportunity. Calls on Quanterix Board to Answer Pressing Questions around Valuation, Process and Governance Issues in Connection with Transaction. Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment. RINCON, Puerto Rico, March 11, 2025----Kent Lake PR LLC  a holder of 7.25% of the outstanding common stock of Quanterix Corporation  , today issued a presentation to Quanterix shareholders in connection to Kent Lake’s opposition to the Company’s proposed transaction  with Akoya Biosciences  .The Transaction is a bad deal for Quanterix shareholders – The Transaction inexplicably values Akoya nearly 5x higher than Quanterix, despite Quanterix’s superior mix, growth and market opportun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kent-lake-issues-investor-presentation-120000653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QTRX","BK4121","BK4539","AKYA"],"gpt_icon":0},{"id":"2517484919","title":"Piper Sandler Downgrades Akoya Biosciences to Neutral From Overweight, Adjusts Price Target to $2.40 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484919","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484919?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:02","pubTimestamp":1741179738,"startTime":"0","endTime":"0","summary":"Akoya Biosciences (AKYA) has an average rating of Hold and mean price target of $3.48, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKYA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akoyabio.com","stockEarnings":[{"period":"1week","weight":-0.1131},{"period":"1month","weight":-0.1629},{"period":"3month","weight":-0.3766},{"period":"6month","weight":-0.479},{"period":"1year","weight":-0.685},{"period":"ytd","weight":-0.3493}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.05841},{"month":2,"riseRate":0.5,"avgChangeRate":-0.077905},{"month":3,"riseRate":0,"avgChangeRate":-0.141872},{"month":4,"riseRate":0,"avgChangeRate":-0.159471},{"month":5,"riseRate":0.25,"avgChangeRate":-0.115603},{"month":6,"riseRate":0.75,"avgChangeRate":0.108226},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004611},{"month":8,"riseRate":0.25,"avgChangeRate":-0.120834},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033565},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023258},{"month":11,"riseRate":0.25,"avgChangeRate":-0.010141},{"month":12,"riseRate":0.75,"avgChangeRate":0.01733}],"exchange":"NASDAQ","name":"Akoya Biosciences, Inc.","nameEN":"Akoya Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akoya Biosciences, Inc.(AKYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Akoya Biosciences, Inc.(AKYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Akoya Biosciences, Inc.,AKYA,Akoya Biosciences, Inc.股票,Akoya Biosciences, Inc.股票老虎,Akoya Biosciences, Inc.股票老虎国际,Akoya Biosciences, Inc.行情,Akoya Biosciences, Inc.股票行情,Akoya Biosciences, Inc.股价,Akoya Biosciences, Inc.股市,Akoya Biosciences, Inc.股票价格,Akoya Biosciences, Inc.股票交易,Akoya Biosciences, Inc.股票购买,Akoya Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akoya Biosciences, Inc.(AKYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Akoya Biosciences, Inc.(AKYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction